

Mohamed L Sorrow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/124565/publications.pdf>

Version: 2024-02-01

70
papers

8,570
citations

159585

30
h-index

114465

63
g-index

72
all docs

72
docs citations

72
times ranked

7106
citing authors

#	ARTICLE	IF	CITATIONS
1	Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT. <i>Blood</i> , 2005, 106, 2912-2919.	1.4	2,427
2	Reduced Mortality after Allogeneic Hematopoietic-Cell Transplantation. <i>New England Journal of Medicine</i> , 2010, 363, 2091-2101.	27.0	1,335
3	Comorbidity and Disease Statusâ€‘Based Risk Stratification of Outcomes Among Patients With Acute Myeloid Leukemia or Myelodysplasia Receiving Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2007, 25, 4246-4254.	1.6	380
4	Comorbidity-Age Index: A Clinical Measure of Biologic Age Before Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2014, 32, 3249-3256.	1.6	361
5	Cord-Blood Transplantation in Patients with Minimal Residual Disease. <i>New England Journal of Medicine</i> , 2016, 375, 944-953.	27.0	352
6	Cytomegalovirus viral load and mortality after haemopoietic stem cell transplantation in the era of pre-emptive therapy: a retrospective cohort study. <i>Lancet Haematology</i> ,the, 2016, 3, e119-e127.	4.6	307
7	Hematopoietic cell transplantationâ€™specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: combined FHCRC and MDACC experiences. <i>Blood</i> , 2007, 110, 4606-4613.	1.4	292
8	Long-term Outcomes Among Older Patients Following Nonmyeloablative Conditioning and Allogeneic Hematopoietic Cell Transplantation for Advanced Hematologic Malignancies. <i>JAMA - Journal of the American Medical Association</i> , 2011, 306, 1874.	7.4	274
9	Five-Year Follow-Up of Patients With Advanced Chronic Lymphocytic Leukemia Treated With Allogeneic Hematopoietic Cell Transplantation After Nonmyeloablative Conditioning. <i>Journal of Clinical Oncology</i> , 2008, 26, 4912-4920.	1.6	257
10	Hematopoietic cell transplantationâ€™comorbidity index and Karnofsky performance status are independent predictors of morbidity and mortality after allogeneic nonmyeloablative hematopoietic cell transplantation. <i>Cancer</i> , 2008, 112, 1992-2001.	4.1	233
11	Late Events after Treatment with CD19-Targeted Chimeric Antigen Receptor Modified T Cells. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, 26-33.	2.0	222
12	Graft-Versus-Host Disease and Graft-Versus-Tumor Effects After Allogeneic Hematopoietic Cell Transplantation. <i>Journal of Clinical Oncology</i> , 2013, 31, 1530-1538.	1.6	197
13	How I assess comorbidities before hematopoietic cell transplantation. <i>Blood</i> , 2013, 121, 2854-2863.	1.4	186
14	Prospective Validation of the Predictive Power of the Hematopoietic Cell Transplantation Comorbidity Index: A Center for International Blood and Marrow Transplant Research Study. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1479-1487.	2.0	173
15	Survival, Nonrelapse Mortality, and Relapse-Related Mortality After Allogeneic Hematopoietic Cell Transplantation: Comparing 2003â€™2007 Versus 2013â€™2017 Cohorts. <i>Annals of Internal Medicine</i> , 2020, 172, 229.	3.9	157
16	Development and Validation of a Novel Acute Myeloid Leukemiaâ€™Composite Model to Estimate Risks of Mortality. <i>JAMA Oncology</i> , 2017, 3, 1675.	7.1	125
17	Hematopoietic Cell Transplant Comorbidity Index Is Predictive of Survival after Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 402-408.e1.	2.0	98
18	Conditioning with Treosulfan and Fludarabine followed by Allogeneic Hematopoietic Cell Transplantation forâ€™High-Risk Hematologic Malignancies. <i>Biology of Blood and Marrow Transplantation</i> , 2011, 17, 341-350.	2.0	95

#	ARTICLE	IF	CITATIONS
19	Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 2117-2125.	2.0	87
20	Pretransplant comorbidities predict severity of acute graft-versus-host disease and subsequent mortality. <i>Blood</i> , 2014, 124, 287-295.	1.4	83
21	Design and Validation of an Augmented Hematopoietic Cell Transplantation-Comorbidity Index Comprising Pretransplant Ferritin, Albumin, and Platelet Count for Prediction of Outcomes after Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 1418-1424.	2.0	62
22	Radiolabeled Anti-CD45 Antibody with Reduced-Intensity Conditioning and Allogeneic Transplantation for Younger Patients with Advanced Acute Myeloid Leukemia or Myelodysplastic Syndrome. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1363-1368.	2.0	54
23	Hematopoietic Cell Transplantation for Myelofibrosis: the Dynamic International Prognostic Scoring System Plus Risk Predicts Post-Transplant Outcomes. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 386-392.	2.0	52
24	Transplant-Associated Thrombotic Microangiopathy Is a Multifactorial Disease Unresponsive to Immunosuppressant Withdrawal. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 570-576.	2.0	51
25	Second Solid Cancers after Allogeneic Hematopoietic Cell Transplantation Using Reduced-Intensity Conditioning. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1777-1784.	2.0	50
26	Long-Term Survival and Late Effects among One-Year Survivors of Second Allogeneic Hematopoietic Cell Transplantation for Relapsed Acute Leukemia and Myelodysplastic Syndromes. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 151-158.	2.0	49
27	Multi-centre validation of the prognostic value of the haematopoietic cell transplantation-specific comorbidity index among recipient of allogeneic haematopoietic cell transplantation. <i>British Journal of Haematology</i> , 2015, 170, 574-583.	2.5	45
28	Reevaluation of the Pretransplant Assessment of Mortality Score after Allogeneic Hematopoietic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 848-854.	2.0	40
29	Avascular Necrosis of Bone after Allogeneic Hematopoietic Cell Transplantation in Children and Adolescents. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 587-592.	2.0	33
30	Allogeneic hematopoietic cell transplantation for acute myeloid leukemia in older adults. <i>Hematology American Society of Hematology Education Program</i> , 2014, 2014, 21-33.	2.5	31
31	Number of Courses of Induction Therapy Independently Predicts Outcome after Allogeneic Transplantation for Acute Myeloid Leukemia in First Morphological Remission. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 373-378.	2.0	30
32	Human Rhinovirus Infections in Hematopoietic Cell Transplant Recipients: Risk Score for Progression to Lower Respiratory Tract Infection. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1011-1021.	2.0	29
33	Evaluation of allogeneic transplantation in first or later minimal residual disease "negative remission following adult-inspired therapy for acute lymphoblastic leukemia. <i>Leukemia and Lymphoma</i> , 2016, 57, 2109-2118.	1.3	28
34	Impact of CD19 CAR T-cell product type on outcomes in relapsed or refractory aggressive B-NHL. <i>Blood</i> , 2022, 139, 3722-3731.	1.4	28
35	Allogeneic Hematopoietic Cell Transplantation following Minimal Intensity Conditioning: Predicting Acute Graft-versus-Host Disease and Graft-versus-Tumor Effects. <i>Biology of Blood and Marrow Transplantation</i> , 2013, 19, 792-798.	2.0	27
36	Long-term sustained disease control in patients with mantle cell lymphoma with or without active disease after treatment with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. <i>Cancer</i> , 2015, 121, 3709-3716.	4.1	27

#	ARTICLE	IF	CITATIONS
37	Multisite 11-year experience of less-intensive vs intensive therapies in acute myeloid leukemia. <i>Blood</i> , 2021, 138, 387-400.	1.4	26
38	Antibiotic Exposure Prior to Respiratory Viral Infection Is Associated with Progression to Lower Respiratory Tract Disease in Allogeneic Hematopoietic Cell Transplant Recipients. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 2293-2301.	2.0	25
39	Comorbidities, Alcohol Use Disorder, and Age Predict Outcomes after Autologous Hematopoietic Cell Transplantation for Lymphoma. <i>Biology of Blood and Marrow Transplantation</i> , 2016, 22, 1582-1587.	2.0	20
40	Long-Term Outcomes of Patients with Persistent Indolent B-Cell Malignancies Undergoing Nonmyeloablative Allogeneic Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2015, 21, 281-287.	2.0	19
41	Prognostic Performance of the Augmented Hematopoietic Cell Transplantation-Specific Comorbidity/Age Index in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation from Alternative Graft Sources. <i>Biology of Blood and Marrow Transplantation</i> , 2019, 25, 1045-1052.	2.0	19
42	Transplant Conditioning with Treosulfan/Fludarabine with or without Total Body Irradiation: A Randomized Phase II Trial in Patients with Myelodysplastic Syndrome and Acute Myeloid Leukemia. <i>Biology of Blood and Marrow Transplantation</i> , 2018, 24, 956-963.	2.0	18
43	The Association between Chronic Conditions, End-of-Life Health Care Use, and Documentation of Advance Care Planning among Patients with Cancer. <i>Journal of Palliative Medicine</i> , 2020, 23, 1335-1341.	1.1	18
44	Intensive Versus Non-Intensive Induction Therapy for Patients (Pts) with Newly Diagnosed Acute Myeloid Leukemia (AML) Using Two Different Novel Prognostic Models. <i>Blood</i> , 2016, 128, 216-216.	1.4	18
45	Prognostic Value of the Hematopoietic Cell Transplantation Comorbidity Index for Patients Undergoing Reduced-Intensity Conditioning Cord Blood Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2017, 23, 654-658.	2.0	14
46	Revised Acute Myeloid Leukemia Composite Model Using the 2017 European LeukemiaNet Risk Classification. <i>JAMA Oncology</i> , 2019, 5, 1062.	7.1	14
47	Impact of Pretransplantation Renal Dysfunction on Outcomes after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2021, 27, 410-422.	1.2	13
48	Hematopoietic cell transplantation comorbidity index and risk of developing invasive fungal infections after allografting. <i>Bone Marrow Transplantation</i> , 2018, 53, 1304-1310.	2.4	12
49	“To Combine or Not to Combine:” Optimizing Risk Assessment before Allogeneic Hematopoietic Cell Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , 2014, 20, 1455-1456.	2.0	11
50	Noninfectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation. <i>Transplantation and Cellular Therapy</i> , 2022, 28, 310-320.	1.2	11
51	Comorbidities, age, and other patient-related predictors of allogeneic hematopoietic cell transplantation outcomes. <i>Expert Review of Hematology</i> , 2018, 11, 805-816.	2.2	10
52	Rituximab-based allogeneic transplant for chronic lymphocytic leukemia with comparison to historical experience. <i>Bone Marrow Transplantation</i> , 2020, 55, 172-181.	2.4	10
53	Pre-transplant comorbidity burden and post-transplant chronic graft-versus-host disease. <i>British Journal of Haematology</i> , 2015, 171, 411-416.	2.5	9
54	Pre-transplant expressions of microRNAs, comorbidities, and post-transplant mortality. <i>Bone Marrow Transplantation</i> , 2019, 54, 973-979.	2.4	4

#	ARTICLE	IF	CITATIONS
55	Survival of patients with newly diagnosed high-grade myeloid neoplasms who do not meet standard trial eligibility. <i>Haematologica</i> , 2021, 106, 2114-2120.	3.5	4
56	Regimenâ€intensity per countâ€recovery and hospitalization index: A new tool to assign regimen intensity for AML. <i>Cancer Medicine</i> , 2020, 9, 6515-6523.	2.8	4
57	Moderate or severe valvular heart disease and outcomes in allogeneic stem cell transplantation. <i>International Journal of Cardiology</i> , 2019, 292, 166-170.	1.7	3
58	Cardio-Oncology and the Intersection of Cancer and Cardiotoxicity. <i>JACC: CardioOncology</i> , 2019, 1, 314-317.	4.0	3
59	Incorporating Physical Function and Cognition Into Mortality Risk Assessment for Acute Myeloid Leukemiaâ€Reply. <i>JAMA Oncology</i> , 2018, 4, 1014.	7.1	2
60	Long-term survival with mixed chimerism in patients with AML and MDS transplanted after conditioning with targeted busulfan, fludarabine, and thymoglobulin. <i>Bone Marrow Transplantation</i> , 2021, , .	2.4	2
61	Need for routine examination of left ventricular ejection fraction in patients with AML. <i>Leukemia</i> , 2020, 34, 1169-1171.	7.2	1
62	Feasibility of geriatric assessment before transplant conditioning regimen in older HCT recipients. <i>Bone Marrow Transplantation</i> , 2021, 56, 726-729.	2.4	1
63	Are hematopoietic cell transplant recipients with Gramâ€negative bacteremia spending more time outpatient while on intravenous antibiotics? Addressing trends over 10 years at a single center. <i>Immunity, Inflammation and Disease</i> , 2021, 9, 1786-1794.	2.7	1
64	Prediction of outcomes after second-line treatment for acute graft-versus-host disease. <i>Blood Advances</i> , 2022, , .	5.2	1
65	Defining vulnerability in allogeneic transplants is more complicated than the two numerical digits of age. <i>Leukemia and Lymphoma</i> , 2015, 56, 2235-2236.	1.3	0
66	Assessment of comorbidities for hematopoietic cell transplants: Achievements and controversies. , 0, , 23-42.		0
67	Graft-versus-Tumor Effects after Allogeneic Hematopoietic Cell Transplantation with Nonmyeloablative Conditioning.. <i>Blood</i> , 2004, 104, 184-184.	1.4	0
68	Marrow Allografts after Nonmyeloablative Conditioning: Effect of Cell Dose on Rejection and Degree of Donor Chimerism.. <i>Blood</i> , 2004, 104, 1202-1202.	1.4	0
69	Pre-transplant Comorbidities: Influence on Decision-Making and Outcomes. <i>Advances and Controversies in Hematopoietic Transplantation and Cell Therapy</i> , 2020, , 57-85.	0.0	0
70	Non-Infectious Pulmonary Toxicity after Allogeneic Hematopoietic Cell Transplantation (HCT): A Center for International Blood and Marrow Transplant Research (CIBMTR) Study. <i>Blood</i> , 2020, 136, 7-8.	1.4	0